51 completed, 8 unknown, 7 terminated, 3 not yet recruiting. 23 Phase 1, 16 Phase 2, 15 Phase 3, 11 Phase 4, 9 Not applicable.
Follow Rifabutin: new trials by email Literature Review of Rifabutin trials Research Report on Rifabutin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Ceftriaxone for Injection, Amoxicillin - Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection | Phase 2 | Not yet recruiting | The University of Queensland | 300 | 2027-04-01 | 2026-03-20 |
| Enhanced Treatment Strategy for Disseminated MAC Infection in HIV Patients: A Randomized Controlled Trial Standard Triple Therapy, Experimental: Standard Triple Therapy Plus Fluoroquinolone - Opportunistic Infections, HIV Related, Disseminated Mycobacterium Avium Complex Infection | Not applicable | Not yet recruiting | Shanghai Public Health Clinical Center | 124 | 2026-04-30 | 2026-05-13 |
| The Effect of Rifabutin in Mycobacterium Abscessus With Inducible Clarithromycin Resistance Rifabutin, No Rifabutin - Mycobacterium Abscessus Lung Disease | Phase 4 | Recruiting | National Taiwan University Hospital | 60 | 2026-01-01 | 2026-06-10 |
| A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004) MK-4646, Rifabutin - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 18 | 2025-10-28 | 2026-01-29 |
| A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults VH4524184, Itraconazole, Rifabutin - HIV Infections | Phase 1 | Completed | ViiV Healthcare | 126 | 2025-07-07 | 2026-03-09 |
| Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study Bismuth, Vonoprazan, Amoxicillin - HELICOBACTER PYLORI INFECTIONS | Not yet recruiting | Xiuli Zuo | 30 | 2025-01-01 | 2024-12-19 | |
| Short-course Regimens for the Treatment of Pulmonary Tuberculosis Rifabutin, Delamanid, Bedaquiline - Tuberculosis, Pulmonary, Tuberculosis Infection | Phase 2 / Phase 3 | Active not recruiting | Centers for Disease Control and Prevention | 288 | 2023-11-21 | 2026-09-21 |
| Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100 BV100 - Bacterial Infections | Phase 1 | Completed | BioVersys AG | 35 | 2023-09-01 | 2025-01-14 |
| Rescue Therapy for Helicobacter Pylori Infection Vonoprazan, Bismuth Potassium Citrate, Tetracycline - Helicobacter Pylori Infection | Phase 4 | Completed | Shanghai Jiao Tong University School of Medicine | 360 | 2023-05-16 | 2025-09-15 |
| To Evaluate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of BV100 BV100 (300 mg), Itraconazole 200 mg - Bacterial Infections | Phase 1 | Completed | BioVersys AG | 16 | 2023-02-01 | 2023-11-21 |
| Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels Vesatolimod, Cobicistat, Voriconazole - Human Immunodeficiency Virus Type 1 (HIV-1) Infection | Phase 1 | Terminated | Gilead Sciences | 18 | 2022-08-19 | 2024-12-03 |
| Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg], Rifabutin 300mg - Drug Drug Interaction | Phase 4 | Completed | University of Southern California | 6 | 2022-05-09 | 2024-08-09 |
| Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR Rifabutin, Rifampicin - Prosthetic Infection | Phase 3 | Recruiting | Tourcoing Hospital | 436 | 2021-11-08 | 2022-05-10 |
| Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment BV100 - Renal Impairment | Phase 1 | Completed | BioVersys AG | 48 | 2021-10-08 | 2023-01-18 |
| Effectiveness of Rifabutin for Treatment of Helicobacter Pylori Rifabutin, Amoxicillin, Esomeprazole - Helicobacter Infections, Resistance Bacterial | Phase 3 | Unknown | Rabin Medical Center | 300 | 2021-05-01 | 2021-03-10 |
| A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD) Bedaquiline, Clarithromycin, Ethambutol - Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD) | Phase 2 / Phase 3 | Completed | Janssen Pharmaceutical K.K. | 129 | 2021-01-08 | 2026-04-15 |
| RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease RHB-204, Placebo - Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis | Phase 3 | Terminated | RedHill Biopharma Limited | 12 | 2020-12-01 | 2025-03-18 |
| A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin Imatinib, Isoniazid, Rifabutin - Tuberculosis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 24 | 2020-10-27 | 2023-10-23 |
| The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males Zanubrutinib, Rifabutin - Healthy, Male | Phase 1 | Completed | BeiGene | 13 | 2020-07-29 | 2024-10-26 |
| Finding the Optimal Regimen for Mycobacterium Abscessus Treatment Amikacin, Tigecycline, Imipenem - Pulmonary Disease Due to Mycobacteria (Diagnosis) | Phase 2 / Phase 3 | Recruiting | The University of Queensland | 300 | 2020-03-02 | 2026-05-11 |
Showing 20 of 74. Sign in to see all of them.
HIV Infections (29) · Tuberculosis (18) · Acquired Immunodeficiency Syndrome (16) · Mycobacterium avium-intracellulare Infection (14) · AIDS-Related Opportunistic Infections (5) · Infections (5) · Bacterial Infections (3) · Tuberculosis, Pulmonary (3) · AIDS-Related Complex (2) · Crohn Disease (2) · Lung Diseases (2) · Mycobacterium Infections, Nontuberculous (2) · Mycoses (2) · Bacteremia (1) · Bronchiectasis (1)
National Institute of Allergy and Infectious Diseases (NIAID) (9) · Pharmacia (6) · Centers for Disease Control and Prevention (5) · Pfizer (4) · ViiV Healthcare (4) · BioVersys AG (3) · RedHill Biopharma Limited (3) · The University of Texas Health Science Center at Tyler (3) · Boehringer Ingelheim (2) · French National Agency for Research on AIDS and Viral Hepatitis (2) · Shanghai Public Health Clinical Center (2) · The University of Queensland (2) · University of California, San Francisco (2) · Abbott (1) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1)
United States (40) · Canada (8) · South Africa (5) · China (4) · Taiwan (3) · Australia (2) · Haiti (2) · Hungary (2) · Israel (2) · Singapore (2) · Tanzania (2) · Uganda (2) · United Kingdom (2) · Vietnam (2) · Austria (1)
Benson CA (2) · Constance Benson (2) · Lisa Husband, MD (2) · Marc Weiner, MD (2) · Richard J Wallace Jr., M.D. (2) · Adupa P Rao, M.D. (1) · Alla Andreeva, PhD (1) · Anchalee Avihingsanon, MD, PhD (1) · Angela Nilius, MD (1) · Anthony D Harries, MD, PhD (1) · Anthony D. Harries, PhD (1) · Brian S Schwartz, MD (1)
PMID 32365359, PMID 11197288, PMID 15276398, PMID 15470330, PMID 15840453, PMID 15844071, PMID 16441468, PMID 19588358, PMID 21188333, PMID 21712242, PMID 22530208, PMID 24465443, PMID 25281400, PMID 25406657, PMID 26482301, PMID 26832753, PMID 27144617, PMID 27687850, PMID 27707777, PMID 29061739, PMID 29519716, PMID 30038469, PMID 31647836, PMID 33037845, PMID 33229425, PMID 34862940, PMID 35604212, PMID 36455068, PMID 37145975, PMID 40915316, PMID 40952649, PMID 40957819, PMID 41732217, PMID 4902833, PMID 8948280
2017 (1), U01AI068636 (1)